LON:SYNC Syncona (SYNC) Share Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free SYNC Stock Alerts GBX 123 +0.20 (+0.16%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range 122.20▼ 12450-Day Range 114.40▼ 130.5952-Week Range 105▼ 162.20Volume646,218 shsAverage Volume923,146 shsMarket Capitalization£806.76 millionP/E RatioN/ADividend Yield1.63%Price TargetGBX 230 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Syncona alerts: Email Address Syncona MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside87.0% UpsideGBX 230 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.28 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSyncona has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 230, Syncona has a forecasted upside of 87.0% from its current price of GBX 123.Amount of Analyst CoverageSyncona has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SYNC. Previous Next 0.8 Dividend Strength Dividend YieldSyncona pays a meaningful dividend of 1.04%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSyncona does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYNC. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for SYNC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syncona insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.18% of the stock of Syncona is held by insiders.Percentage Held by Institutions64.85% of the stock of Syncona is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Syncona is -492.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syncona is -492.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyncona has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Syncona Stock (LON:SYNC)Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.Read More SYNC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYNC Stock News HeadlinesMarch 14, 2024 | lse.co.ukSyncona portfolio company Autolus posts widened loss for 2023February 21, 2024 | finanznachrichten.deFreeline Therapeutics Holdings plc: Acquisition of Freeline by Syncona Becomes EffectiveMarch 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 10, 2024 | thetimes.co.ukShortlist revealed for NED awardsFebruary 8, 2024 | finanznachrichten.deBioNTech SE: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage ProgramsFebruary 8, 2024 | lse.co.ukSyncona portfolio strengthens in third quarter thanks to AutolusFebruary 8, 2024 | lse.co.ukUPDATE: Syncona portfolio strengthens thanks to AutolusJanuary 19, 2024 | lse.co.ukSyncona says Freeline trial for Gaucher disease treatment positiveMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. December 14, 2023 | bbc.comSynconaDecember 4, 2023 | markets.businessinsider.comSyncona Portfolio Firm Beacon's AGTC-501 Trial Shows Positive Data In X-Linked Retinitis PigmentosaNovember 23, 2023 | msn.comBRIEF-Syncona Ltd To Acquire Freeline TherapeuticsNovember 22, 2023 | marketwatch.comFreeline Therapeutics Shares Rise on Takeover by SynconaNovember 22, 2023 | msn.comGene Therapy Player Freeline Therapeutics Goes Private In $28M DealNovember 22, 2023 | marketwatch.comFreeline Therapeutics Agrees to Buyout by SynconaNovember 22, 2023 | markets.businessinsider.comFreeline Therapeutics To Be Bought By Syncona For $28.3 Mln In Cash; Freeline Stock UpNovember 22, 2023 | msn.comFreeline Therapeutics to be acquired by Syncona for $28.3M in cashNovember 22, 2023 | finance.yahoo.comSyncona to Acquire Freeline TherapeuticsNovember 16, 2023 | lse.co.ukSyncona reports declining asset value as investment head steps downOctober 18, 2023 | markets.businessinsider.comSyncona Proposes To Acquire Freeline TherapeuticsOctober 18, 2023 | msn.comFreeline gains on non-binding buyout offer from SynconaOctober 18, 2023 | marketwatch.comSyncona Seeks to Buy Remaining Shares of Freeline TherapeuticsOctober 16, 2023 | finance.yahoo.comSwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating OfficerOctober 16, 2023 | marketwatch.comSyncona Portfolio Company to Present Updated Data on Cancer StudyOctober 4, 2023 | finanznachrichten.deSwanBio Therapeutics: SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for AdrenomyeloneuropathyOctober 4, 2023 | finance.yahoo.comSwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for AdrenomyeloneuropathySeptember 29, 2023 | marketwatch.comSyncona to Buy Back Up to GBP40 Mln in SharesSee More Headlines Receive SYNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syncona and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Asset Management Sub-IndustryN/A Current SymbolLON:SYNC Previous SymbolLON:BACT CUSIPN/A CIKN/A Webwww.bacitltd.com Phone17168531362FaxN/AEmployees1,208Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 230 High Stock Price TargetGBX 230 Low Stock Price TargetGBX 230 Potential Upside/Downside+87.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-165,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-12.88% Return on Assets-7.77% Debt Debt-to-Equity Ratio64.05 Current Ratio1.24 Quick Ratio0.53 Sales & Book Value Annual Sales£-144,460,000.00 Price / Sales-5.58 Cash FlowGBX 104.73 per share Price / Cash Flow1.17 Book ValueGBX 179 per share Price / Book0.69Miscellaneous Outstanding Shares655,900,000Free FloatN/AMarket Cap£806.76 million OptionableNot Optionable Beta0.26 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Thomas Henderson (Age 57)Co-Founder & Non-Exec. Director Dr. Martin Patrick Murphy Ph.D. (Age 55)Chief Exec. Officer Mr. John McDonald (Age 58)Co-Founder Mr. Rolf Kristian Berndtson Soderstrom ACA (Age 57)BA, Chief Financial Officer Mr. Ben WoolvenBus. Strategy and Operations PartnerDr. Christopher J. Hollowood Ph.D. (Age 48)CIO & Managing Partner of Syncona Investment Management Ltd. Ms. Annabel ClarkHead of Investor Relations and CommunicationsMr. Andrew CossarGen. CounselMs. Fenella DernieExec. OfficerMr. Edward Eliot Hodgkin DPhil (Age 60)Managing Partner More ExecutivesKey CompetitorsJPMorgan JapaneseLON:JFJICG Enterprise TrustLON:ICGTThe Global Smaller Companies TrustLON:GSCTTwentyFour IncomeLON:TFIFBellevue Healthcare TrustLON:BBHView All Competitors SYNC Stock Analysis - Frequently Asked Questions Should I buy or sell Syncona stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syncona in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYNC shares. View SYNC analyst ratings or view top-rated stocks. What is Syncona's stock price target for 2024? 1 Wall Street research analysts have issued 12-month price objectives for Syncona's stock. Their SYNC share price targets range from GBX 230 to GBX 230. On average, they predict the company's stock price to reach GBX 230 in the next year. This suggests a possible upside of 87.0% from the stock's current price. View analysts price targets for SYNC or view top-rated stocks among Wall Street analysts. How have SYNC shares performed in 2024? Syncona's stock was trading at GBX 123.40 on January 1st, 2024. Since then, SYNC shares have decreased by 0.3% and is now trading at GBX 123. View the best growth stocks for 2024 here. Is Syncona a good dividend stock? Syncona (LON:SYNC) pays an annual dividend of GBX 2 per share and currently has a dividend yield of 1.04%. Read our dividend analysis for SYNC. What other stocks do shareholders of Syncona own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syncona investors own include Rexahn Pharmaceuticals (REXN), Barrick Gold (ABX), Agnico Eagle Mines (AEM), Franco-Nevada (FNV), Goldex Resources (GDX), VanEck Gold Miners ETF (GDX), Goldcorp (GG), Barrick Gold (GOLD) and Northern Dynasty Minerals (NAK). How do I buy shares of Syncona? Shares of SYNC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SYNC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syncona Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.